[an error occurred while processing this directive] | [an error occurred while processing this directive]
Impact of three to four cycles of neoadjuvant chemotherapy on survival of patients with N2-N3 nasopharyngeal carcinoma
Wei Jiawang, Huang Rong, Yu Xin, Wang Qiaoxuan, Xiao Weiwei, Lu Lixia, Gao Yuanhong, Chang Hui
Department of Radiation Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Guangzhou 510060,China (Wei JW,Yu X,Wang QX,Xiao WW,Lu LX,Gao YH,Chang H);
Department of Oncology,Ganzhou People's Hospital,Ganzhou 341000,China (Huang R)
Objective To evaluate the impact of three to four cycles of neoadjuvant chemotherapy (NACT) on the survival of patients with N2-N3 nasopharyngeal carcinoma (NPC). Methods The clinical data of 915 patients with T1-4N2-3M0 NPC from 2007 to 2010 were retrospectively analyzed. A total of 179 patients treated with 3-4 cycles of NACT (NACT≥3 group) were matched with 358 patients treated with 2 cycles of NACT (NACT=2 group) and 179 patients treated without NACT (NACT=0 group, concurrent chemoradiotherapy group) for age, N stage, pathological subtype, and NACT regimen. The Kaplan-Meier method was used to calculate overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), and distant metastasis-free survival (DMFS) rates, the log-rank test was used for survival difference analysis and univariate prognostic analysis, and the Cox proportional hazards model was used for multivariate prognostic analysis. Results For the NACT≥3, NACT=2, and NACT=0 groups, the 5-year OS rates were 89.4%, 81.6%, and 73.7%, respectively (P=0.000), the 5-year DFS rates were 83.2%, 69.8%, and 64.2%, respectively (P=0.000), the 5-year RFS rates were 86.0%, 76.0%, and 69.3%, respectively (P=0.001), and the 5-year DMFS rates were 86.6%, 76.0%, and 68.3%, respectively (P=0.000). Three to four cycles of NACT was an independent protective factor for OS, DFS, RFS, and DMFS in patients with N2-N3 NPC. Conclusion Three to four cycles of NACT can significantly improve the survival of patients with N2-N3 NPC.
Wei Jiawang,Huang Rong,Yu Xin et al. Impact of three to four cycles of neoadjuvant chemotherapy on survival of patients with N2-N3 nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(4): 380-383.
Wei Jiawang,Huang Rong,Yu Xin et al. Impact of three to four cycles of neoadjuvant chemotherapy on survival of patients with N2-N3 nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(4): 380-383.
[1] Lin JC,Jan JS,Hsu CY,et al. Phase Ⅲ study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma:positive effect on overall and progression-free survival[J].J Clin Oncol,2003,21(4):631-637.DOI:10.1200/JCO.2003.06.158
[2] Guigay J,Temam S,Bourhis J,et al. Nasopharyngeal carcinoma and therapeutic management:the place of chemotherapy[J].Ann Oncol,2006,17 Suppl 10:x304-307.DOI:10.1093/annonc/mdl278
[3] Cheng SH,Jian JJM,Tsai SYC,et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy[J].Int J Radiat Oncol Biol Phys,2000,48(5):1323-1330.DOI:10.1016/S0360-3016(00)00779-3
[4] 孙学明,黄莹,陈春燕,等.N晚期鼻咽癌调强放疗远期疗效评价[J].中华放射肿瘤学杂志,2013,22(3):225-229.DOI:10.3760/cma.j.issn.1004-4221.2013.03.014.
Sun XM,Huang Y,Chen CY,et al. Long-term outcomes of patients with advanced N-stage nasopharyngeal carcinoma treated by intensity-modulated radiotherapy alone or with chemotherapy[J].Chin J Radiat Oncol,2013,22(3):225-229.DOI:10.3760/cma.j.issn.1004-4221.2013.03.014
[5] Ghossein RA,Bhattacharya S,Rosai J.Molecular detection of micrometastases and circulating tumor cells in solid tumors[J].Clin Cancer Res,1999,5(8):1950-1960
[6] Hui EP,Ma BB,Leung SF,et al. Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma[J].J Clin Oncol,2009,27(2):242-249.DOI:10.1200/JCO.2008.18.1545
[7] Fountzilas G,Ciuleanu E,Bobos M,et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma:a randomized phase Ⅱ study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation[J].Ann Oncol,2012,23(2):427-435.DOI:10.1093/annonc/mdr116
[8] Tan T,Lim WT,Fong KW,et al. Concurrent chemo-radiation with or without induction gemcitabine,carboplatin,and paclitaxel:a randomized,phase 2/3 trial in locally advanced nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2015,91(5):952-960.DOI:10.1016/j.ijrobp.2015.01.002
[9] da Costa Miranda V,de Souza FêdeB,Dos Anjos CH,et al. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery:safety and effectiveness[J].Gynecol Oncol,2014,132(2):287-291.DOI:10.1016/j.ygyno.2013.12.002.
[10] Honkoop AH,Luykx-de Bakker SA,Hoekman K,et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer[J].Oncologist,1999,4(2):106-111.
2017, Vol. 26 
